Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece. (Q53674348)
Jump to navigation
Jump to search
scientific article published on 30 January 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece. |
scientific article published on 30 January 2012 |
Statements
Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece. (English)
Kostas Athanasakis
Vasilios Fragoulakis
Vasiliki Tsiantou
Panagiotis Masaoutis
Nikolaos Maniadakis
John Kyriopoulos
30 January 2012
34
2
446-456